Sterling Pharma Solutions unveils $13.4 million investment plan for Dudley, UK site

Sterling Pharma Solutions, a contract development and manufacturing organization (CDMO), has introduced the next phase of its multi-year investment strategy at its location in Dudley, UK. The $13.4 million plan will include the building and commissioning of new process development laboratories, and the installation of additional commercial-scale manufacturing equipment, in order to address the growth in demand for small molecule active pharmaceutical ingredient (API) manufacturing.

The project—which has an anticipated completion date of mid-2022—features the installation of a 4.5 cubic-meter (159 cubic-foot) hydrogenator, that is capable of pressure reactions up to 10 bar, along with supplemental conical and filter dryers within the current manufacturing plant. The CDMO's new kilo-scale and technology laboratories will be built in the site’s Material Science Centre, which was constructed as an earlier part of the investment strategy in 2020.